首页> 外文期刊>China Journal of Accounting Research >Reliability of R&D capitalization: Evidence from ex post impairment in China
【24h】

Reliability of R&D capitalization: Evidence from ex post impairment in China

机译:研发资本化的可靠性:来自中国事后减值的证据

获取原文
       

摘要

Unlike prior studies that investigate research and development (R&D) accounting as a dichotomous choice between capitalizing vs. expensing, this study identifies low-reliability R&D capitalization by the occurrence of ex post impairment of capitalized R&D costs. I find that low-reliability capitalization is associated with higher discretionary accruals but fails to signal future innovation, whereas normal capitalization without subsequent impairment lacks earnings aggressiveness and predicts future innovation positively, compared to expensing firms. Next, this study shows that Big 4 and industry specialist auditors improve reliability by notably decreasing the likelihood of low-reliability R&D capitalization. The results remain robust after controlling for R&D investment intensity and potential endogeneity in the capitalization decision. Additional tests show that managers strategically time the recognition of impairment for big-bath and earnings-smoothing purposes, and that analyst coverage does not help differentiate between low-reliability and normal R&D capitalization. Collectively, this paper increases our understanding of R&D accounting and auditing and contributes to the debate on the reliability of R&D capitalization.
机译:与以往的研究与开发(R&D)会计调查是资本化还是支出之间的二选一研究不同,本研究通过资本化R&D成本事后减损的出现来识别低可靠性R&D资本化。我发现,低可靠性的资本化与较高的可支配应计费用有关,但不能表示未来的创新,而与昂贵的公司相比,没有后续减值的正常资本化缺乏收益积极性,并且可以积极预测未来的创新。接下来,这项研究表明,四大巨头和行业专家审计师通过显着降低低可靠性R&D资本化的可能性来提高可靠性。在控制研发投资强度和资本化决策中的潜在内生性之后,结果仍然很稳健。额外的测试表明,管理人员出于战略目的考虑时间,以大刀阔斧和平滑收益为目的,并且分析师的研究范围无法帮助区分低可靠性和正常研发资本。总体而言,本文增加了我们对R&D会计和审计的理解,并为有关R&D资本化可靠性的辩论做出了贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号